Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

Executive Summary

• Helix BioPharma presented new data on its CEACAM6‑directed antibody‑drug conjugate (ADC) program at the 16th Annual World ADC London conference.
• The presentation, delivered by Director of ADC Discovery Jonathan Davis, PhD, highlighted the therapeutic potential of CEACAM6 and showcased Helix’s proprietary anti‑CEACAM6 VHH nanobody platform.
• The data underscored continued progress on Helix’s lead candidate L‑DOS47 (Phase I/II in NSCLC) and its next‑generation bi‑specific ADC discovery efforts.

Key Details

• Conference: 16th Annual World ADC London, London, United Kingdom – opening day seminar.
• Presenter: Jonathan Davis, PhD – Director of ADC Discovery, Helix BioPharma.
• Presentation Title: “Next‑Generation ADCs: Unlocking the Potential of CEACAM6‑Directed Targeted Therapies.”
• Scientific Highlights:
• CEACAM6 identified as a high‑value target due to elevated expression in diverse epithelial cancers and limited normal tissue presence.
• Helix’s anti‑CEAM6 VHH (single‑domain camelid antibody fragment) demonstrated tumor‑selective binding, supporting targeted ADC design with reduced off‑target toxicity.
• Program Context:
• Builds on clinical foundation of Tumor Defense Breaker™ L‑DOS47, which has shown favorable safety and encouraging activity in Phase I/II NSCLC studies.
• Supports ongoing discovery of next‑generation bi‑specific ADCs leveraging the VHH platform.
• Company Pipeline Mentioned:
• L‑DOS47 – clinical‑stage antibody‑enzyme conjugate targeting CEACAM6 (Phase Ib completed).
• LEUMUNA™ – oral immune checkpoint modulator for post‑transplant leukemia relapse (pre‑IND).
• GEMCEDA™ – oral gemcitabine prodrug with IV‑comparable bioavailability (pre‑IND).
• Availability: Full presentation PDF posted on Helix website: https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.

Notable Quotes

“CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard‑to‑treat cancers,” said Dr. Jonathan Davis.
“Our proprietary VHH‑based targeting approach enables highly selective tumor binding, supporting the development of next‑generation ADCs designed to maximize therapeutic impact while minimizing off‑target effects.”